Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 30

1.

Towards a More User-Friendly Medication Information Delivery to People Living with Multiple Sclerosis: A Case Study with Alemtuzumab.

Azman A, Poyade M, Overell J.

Adv Exp Med Biol. 2019;1120:67-82. doi: 10.1007/978-3-030-06070-1_6.

PMID:
30919295
2.

Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial.

Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, Ströbel P, Mazia C, Oger J, Cea JG, Heckmann JM, Evoli A, Nix W, Ciafaloni E, Antonini G, Witoonpanich R, King JO, Beydoun SR, Chalk CH, Barboi AC, Amato AA, Shaibani AI, Katirji B, Lecky BRF, Buckley C, Vincent A, Dias-Tosta E, Yoshikawa H, Waddington-Cruz M, Pulley MT, Rivner MH, Kostera-Pruszczyk A, Pascuzzi RM, Jackson CE, Verschuuren JJGM, Massey JM, Kissel JT, Werneck LC, Benatar M, Barohn RJ, Tandan R, Mozaffar T, Silvestri NJ, Conwit R, Sonett JR, Jaretzki A 3rd, Newsom-Davis J, Cutter GR; MGTX Study Group.

Lancet Neurol. 2019 Mar;18(3):259-268. doi: 10.1016/S1474-4422(18)30392-2. Epub 2019 Jan 25.

PMID:
30692052
3.

Factors influencing multiple sclerosis disease-modifying treatment prescribing decisions in the United Kingdom: A qualitative interview study.

Cameron E, Rog D, McDonnell G, Overell J, Pearson O, French DP.

Mult Scler Relat Disord. 2019 Jan;27:378-382. doi: 10.1016/j.msard.2018.11.023. Epub 2018 Nov 22.

4.

International consensus on quality standards for brain health-focused care in multiple sclerosis.

Hobart J, Bowen A, Pepper G, Crofts H, Eberhard L, Berger T, Boyko A, Boz C, Butzkueven H, Celius EG, Drulovic J, Flores J, Horáková D, Lebrun-Frénay C, Marrie RA, Overell J, Piehl F, Rasmussen PV, Sá MJ, Sîrbu CA, Skromne E, Torkildsen Ø, van Pesch V, Vollmer T, Zakaria M, Ziemssen T, Giovannoni G.

Mult Scler. 2018 Nov 1:1352458518809326. doi: 10.1177/1352458518809326. [Epub ahead of print]

PMID:
30381987
5.

Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis.

Connick P, De Angelis F, Parker RA, Plantone D, Doshi A, John N, Stutters J, MacManus D, Prados Carrasco F, Barkhof F, Ourselin S, Braisher M, Ross M, Cranswick G, Pavitt SH, Giovannoni G, Gandini Wheeler-Kingshott CA, Hawkins C, Sharrack B, Bastow R, Weir CJ, Stallard N, Chandran S, Chataway J; UK Multiple Sclerosis Society Clinical Trials Network.

BMJ Open. 2018 Aug 30;8(8):e021944. doi: 10.1136/bmjopen-2018-021944.

6.

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.

Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallström E, Dahlke F; EXPAND Clinical Investigators.

Lancet. 2018 Mar 31;391(10127):1263-1273. doi: 10.1016/S0140-6736(18)30475-6. Epub 2018 Mar 23. Erratum in: Lancet. 2018 Nov 17;392(10160):2170.

PMID:
29576505
7.

Inhibition of complement in Guillain-Barré syndrome: the ICA-GBS study.

Davidson AI, Halstead SK, Goodfellow JA, Chavada G, Mallik A, Overell J, Lunn MP, McConnachie A, van Doorn P, Willison HJ.

J Peripher Nerv Syst. 2017 Mar;22(1):4-12. doi: 10.1111/jns.12194.

PMID:
27801990
8.

Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature.

Kavanagh D, McGlasson S, Jury A, Williams J, Scolding N, Bellamy C, Gunther C, Ritchie D, Gale DP, Kanwar YS, Challis R, Buist H, Overell J, Weller B, Flossmann O, Blunden M, Meyer EP, Krucker T, Evans SJ, Campbell IL, Jackson AP, Chandran S, Hunt DP.

Blood. 2016 Dec 15;128(24):2824-2833. Epub 2016 Sep 23.

9.

Randomized Trial of Thymectomy in Myasthenia Gravis.

Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, Ströbel P, Mazia C, Oger J, Cea JG, Heckmann JM, Evoli A, Nix W, Ciafaloni E, Antonini G, Witoonpanich R, King JO, Beydoun SR, Chalk CH, Barboi AC, Amato AA, Shaibani AI, Katirji B, Lecky BR, Buckley C, Vincent A, Dias-Tosta E, Yoshikawa H, Waddington-Cruz M, Pulley MT, Rivner MH, Kostera-Pruszczyk A, Pascuzzi RM, Jackson CE, Garcia Ramos GS, Verschuuren JJ, Massey JM, Kissel JT, Werneck LC, Benatar M, Barohn RJ, Tandan R, Mozaffar T, Conwit R, Odenkirchen J, Sonett JR, Jaretzki A 3rd, Newsom-Davis J, Cutter GR; MGTX Study Group.

N Engl J Med. 2016 Aug 11;375(6):511-22. doi: 10.1056/NEJMoa1602489. Erratum in: N Engl J Med. 2017 May 25;376(21):2097. [Dosage error in article text].

10.

Clinical Reasoning: A 48-year-old man with walking difficulty.

Kalladka D, Iqbal A, MacDuff E, Overell J.

Neurology. 2015 Dec 1;85(22):e165-9. doi: 10.1212/WNL.0000000000002168. No abstract available.

PMID:
26628493
11.

A pragmatic approach to dealing with fingolimod-related lymphopaenia in Europe.

Giovannoni G, de Jong B, Derfuss T, Izquierdo G, Mazibrada G, Molyneux P, Nicholas R, Overell J, Ziemssen T, Juliusson G.

Mult Scler Relat Disord. 2015 Jan;4(1):83-4. doi: 10.1016/j.msard.2014.09.215. Epub 2014 Oct 13. No abstract available.

PMID:
25787058
12.

Outcome after conservative management or intervention for unruptured brain arteriovenous malformations.

Al-Shahi Salman R, White PM, Counsell CE, du Plessis J, van Beijnum J, Josephson CB, Wilkinson T, Wedderburn CJ, Chandy Z, St George EJ, Sellar RJ, Warlow CP; Scottish Audit of Intracranial Vascular Malformations Collaborators.

JAMA. 2014 Apr 23-30;311(16):1661-9. doi: 10.1001/jama.2014.3200.

PMID:
24756516
13.

Thrombotic microangiopathy associated with interferon beta.

Hunt D, Kavanagh D, Drummond I, Weller B, Bellamy C, Overell J, Evans S, Jackson A, Chandran S.

N Engl J Med. 2014 Mar 27;370(13):1270-1. doi: 10.1056/NEJMc1316118. No abstract available.

14.

Untreated clinical course of cerebral cavernous malformations: a prospective, population-based cohort study.

Al-Shahi Salman R, Hall JM, Horne MA, Moultrie F, Josephson CB, Bhattacharya JJ, Counsell CE, Murray GD, Papanastassiou V, Ritchie V, Roberts RC, Sellar RJ, Warlow CP; Scottish Audit of Intracranial Vascular Malformations (SAIVMs) collaborators.

Lancet Neurol. 2012 Mar;11(3):217-24. doi: 10.1016/S1474-4422(12)70004-2. Epub 2012 Jan 31.

15.

Peripheral neuropathy: pattern recognition for the pragmatist.

Overell JR.

Postgrad Med J. 2012 Feb;88(1036):88-96. doi: 10.1136/pgmj.2011.241612rep.

PMID:
22262780
16.

A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS.

Freedman MS, Bar-Or A, Oger J, Traboulsee A, Patry D, Young C, Olsson T, Li D, Hartung HP, Krantz M, Ferenczi L, Verco T; MAESTRO-01 Investigators.

Neurology. 2011 Oct 18;77(16):1551-60. doi: 10.1212/WNL.0b013e318233b240. Epub 2011 Oct 5.

PMID:
21975206
17.

An open label clinical trial of complement inhibition in multifocal motor neuropathy.

Fitzpatrick AM, Mann CA, Barry S, Brennan K, Overell JR, Willison HJ.

J Peripher Nerv Syst. 2011 Jun;16(2):84-91. doi: 10.1111/j.1529-8027.2011.00328.x.

PMID:
21692905
18.

Peripheral neuropathy: pattern recognition for the pragmatist.

Overell JR.

Pract Neurol. 2011 Apr;11(2):62-70. doi: 10.1136/jnnp.2011.241612. Review.

PMID:
21385962
19.

Variant CJD in an individual heterozygous for PRNP codon 129.

Kaski D, Mead S, Hyare H, Cooper S, Jampana R, Overell J, Knight R, Collinge J, Rudge P.

Lancet. 2009 Dec 19;374(9707):2128. doi: 10.1016/S0140-6736(09)61568-3. No abstract available.

PMID:
20109837
20.

Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study.

RMC Trial Group.

Lancet Neurol. 2009 Feb;8(2):158-64. doi: 10.1016/S1474-4422(08)70299-0. Epub 2009 Jan 10.

PMID:
19136303

Supplemental Content

Loading ...
Support Center